America First Investment Advisors LLC Makes New $22.67 Million Investment in Thermo Fisher Scientific Inc. $TMO

America First Investment Advisors LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 55,901 shares of the medical research company’s stock, valued at approximately $22,666,000. Thermo Fisher Scientific comprises 4.5% of America First Investment Advisors LLC’s investment portfolio, making the stock its 16th biggest holding.

Several other large investors have also made changes to their positions in TMO. Traub Capital Management LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $107,000. Perennial Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 22.8% in the second quarter. Perennial Investment Advisors LLC now owns 1,463 shares of the medical research company’s stock worth $593,000 after acquiring an additional 272 shares during the last quarter. MainStreet Investment Advisors LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at $1,353,000. United Advisor Group LLC boosted its holdings in Thermo Fisher Scientific by 43.5% in the 2nd quarter. United Advisor Group LLC now owns 709 shares of the medical research company’s stock valued at $287,000 after purchasing an additional 215 shares during the period. Finally, Empowered Funds LLC grew its position in Thermo Fisher Scientific by 28.2% in the 2nd quarter. Empowered Funds LLC now owns 14,606 shares of the medical research company’s stock worth $5,922,000 after purchasing an additional 3,213 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 4,638 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the transaction, the chief operating officer owned 23,480 shares of the company’s stock, valued at $13,956,981.60. This represents a 16.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the sale, the vice president owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. The trade was a 7.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 51,845 shares of company stock valued at $28,956,952 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TMO. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. TD Cowen upped their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. HSBC reissued a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays raised their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Stock Up 1.6%

Shares of NYSE:TMO opened at $576.01 on Wednesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm has a market cap of $216.41 billion, a P/E ratio of 33.28, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $531.35 and its two-hundred day moving average price is $470.43.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.